Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-05-08
2011-12-06
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252020, C514S252190, C514S256000, C514S253040, C514S254080, C514S302000, C514S333000, C514S338000, C514S364000, C514S375000, C544S123000, C544S238000, C544S295000, C544S322000, C544S333000, C544S362000, C544S368000, C546S116000, C546S194000, C546S271700, C548S131000, C548S221000
Reexamination Certificate
active
08071593
ABSTRACT:
Described are compounds which inhibit, regulate and/or modulate kinase signal transduction, for example of Met kinase. The compounds are of the formulae A1 to A148 and B1 described herein, including 2-oxobenzoxazol-3-ylmethyl]phenyl}carbamate and 2-oxooxazolo[4,5-b]pyridin-3-ylmethyl)phenyl]carbamate compounds, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. Also described are compositions containing these compounds. Also described are methods for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role by administering these compounds.
REFERENCES:
patent: 2004/0152739 (2004-08-01), Hanau et al.
patent: 10-259176 (1998-09-01), None
“Cancer.” MedLine Plus. (2009). Accessed Mar. 17, 2009. <http://www.nlm.nih.gov/medlineplus/cancer.html>.
Ettmayer et al. “Lessons Learned from Marketed and Investigational Prodrugs.” J. Med. Chem., (2004), 47(10): 2393-2404.
Golub et al. “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring.” Science (1999), vol. 286, 521-537.
Johnson et al. “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.” British Journal of Cancer (2001), 84(10), 1424-1431.
Lala et al. “Role of nitric oxide in tumor progression: Lessons from experimental tumors.” Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Sausville et al. “Contributions of Human Tumor Xenografts to Anticancer Drug Development.” Cancer Res. 2006, 66(7), Apr. 1, 2006.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Stella, Valentino. “Prodrugs as therapeutics.” Expert Opin. Ther. Patents (2004), 14(3): 277-280.
Testa, Bernard. “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68 (2004): 2097-2106.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. vol. 1: Principles and Practice. pp. 975-977.
Blaukat Andree
Dorsch Dieter
Schadt Oliver
Stieber Frank
Anderson Rebecca
Merck Patent Gesellschaft mit beschrankter Haftung
Millen White Zelano & Branigan P.C.
Otton Alicia L
LandOfFree
2-oxo-3-benzylbenzoxazol-2-one derivatives and related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-oxo-3-benzylbenzoxazol-2-one derivatives and related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-oxo-3-benzylbenzoxazol-2-one derivatives and related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296241